S&P Futures
5,895.50 -10.50 (-0.18%) Dow Futures
43,473.00 -45.00 (-0.10%) Nasdaq Futures
20,410.75 -72.75 (-0.36%) Russell 2000 Futures
2,291.70 +0.50 (+0.02%) Crude Oil
70.22 +1.00 (+1.44%) Gold
2,749.60 +19.60 (+0.72%)
Estrella Immunopharma, Inc. (ESLAW)
- Business Wire
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
EMERYVILLE, Calif., September 27, 2024--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial has achieved a complete response (CR) one month after receiving an infusion of EB103 CD19- Redirected ARTEMIS® T Cells.
- Business Wire
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
EMERYVILLE, Calif., August 14, 2024--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella", "Estrella Immunopharma", or the "Company"), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the Company dosed the first patient in its Phase I/II clinical
